AZ agreement with Aralez for Toprol-XL in US This

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 4, 2016 at 2:15 AM

AZ agreement with Aralez for Toprol-XL in US

This announcement contains inside information 4 October 2016 07:05 ASTRAZENECA ENTERS AGREEMENT WITH ARALEZ FOR BETA-BLOCKER MEDICINE TOPROL-XL IN THE US AstraZeneca today announced that it has entered into an agreement with Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez Pharmaceuticals Inc., for the rights to branded and authorised generic Toprol-XL (metoprolol succinate) in the US. Toprol-XL is a beta-blocker medicine for the control of hypertension (high blood pressure), angina (chest pain) and heart failure. It was first approved in the US in 1992. Under the terms of the agreement, Aralez will pay AstraZeneca $175 million to acquire the rights to Toprol-XL tablets in the US, and the authorised generic medicine marketed by Par Pharmaceuticals. Aralez will also pay AstraZeneca up to $48 million in milestone and sales-related payments, as well as mid-teen percentage royalties on sales. AstraZeneca will continue to manufacture and supply Toprol-XL and the authorised generic medicine to Aralez. Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca said: "This agreement allows us to focus our resources on our new launches and pipeline of innovative medicines, while working with Aralez, a partner with expertise in cardiovascular disease, to ensure continued patient access to Toprol-XL." Adrian Adams, Chief Executive Officer of Aralez Pharmaceuticals Inc. said: "We are pleased to be entering into this agreement with AstraZeneca. Toprol-XL represents a strong addition to our growing anchor position in cardiovascular disease. We look forward to helping patients continue to benefit from this important medicine." Financial considerations In 2015, US Product Sales for Toprol-XL and the AstraZeneca share from the sale of the authorised generic medicine totalled $89 million. The transaction is expected to complete in the fourth quarter of 2016, subject to customary closing conditions. As AstraZeneca will retain an ongoing interest in Toprol-XL in the US through the ongoing milestones, royalties and product supply, the upfront payment of $175 million, milestones and sales-related payments of up to $48 million and mid-teen percentage royalties will be reported as Externalisation Revenue in the Company's financial statements. The agreement does not include the transfer of any AstraZeneca employees or facilities and does not impact AstraZeneca's financial guidance for 2016. About Aralez Pharmaceuticals Inc. Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercialising products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Mississauga, Ontario, Canada, the U.S. Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also selectively active in Neuroscience and Autoimmunity. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com CONTACTS Media Enquiries Neil Burrows UK/Global +44 203 749 5637 Vanessa Rhodes UK/Global +44 203 749 5736 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations UK Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Nick Stone Respiratory +44 203 749 5716 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris Neuroscience & Autoimmunity +44 203 749 5711 US Lindsey Trickett Cardiovascular & Metabolic +1 240 543 7970 Diseases Mitchell Chan Oncology +1 240 477 3771 Toll free +1 866 381 7277 Adrian Kemp Company Secretary AstraZeneca PLC -ENDS-

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Egan-Jones Backs DGB's Push for Ethan Allen Shakeup

Proxy Fight Brews Over Ethan Allen's Future Here we are, embroiled in another classic showdown in the corporate boardroom, and this time it's over at Ethan Allen—home of those plush couches and dining tables. Egan-Jones proxy services just threw its weight behind all five of DGB Investment's nominees for Ethan Allen’s board. This kind of tug-of-war isn't new, but each...

Miraculous Medical Team Effort Saves Newborn's Life

A Medical Feat: Teamwork at Its Pinnacle You want a story that restores your faith in humanity? Well, this one from Memorial Healthcare System and Joe DiMaggio Children's Hospital might just do the trick. The tale of baby Jay'ce, born with a neck mass threatening his breath, is straight out of a medical drama—albeit without the Hollywood scriptwriters' spin. It’s rare...

Ares Commercial Real Estate Gears Up for Q3 Earnings

Earnings Season Descends on Ares Commercial Real Estate The hush before the storm is here, comrades. Ares Commercial Real Estate Corporation (NYSE: ACRE) has set the ticker tape rolling as they prepare to unveil the fiscal secrets of their third quarter on November 6, 2026. If you’ve got skin in the game or just an ear for market music, mark your calendars because the...

Tragedy in Jordan: A Call for Unity and Support

A Dark Day in Jordan It's a gut punch, hearing news of yet another brutal attack targeting the Christian community in Jordan's Karak province. This act of terror isn't just a regional dagger—it cuts deep into the fabric of shared humanity. On Friday, the tranquil air of a sacred gathering was shattered, leaving behind grief and a call to action for those who refuse to...

S&P Global's New Dashboard: Unpacking Data Insights

An Interactive Take on Digital Infrastructure The geniuses over at S&P Global Ratings have just unleashed a shiny new tool for number crunchers and market hawks who can't get enough data center action—an interactive dashboard. Maybe not everyone’s cup of tea, but hey, in the dog-eat-dog world of digital infrastructure, any edge counts. What's in the Data Center Soup?...

Cowfest 2026 Delighted by Frederick's Flying Cows

Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...

Qatar's Cultural Ventures Go Big Through 2030

Cultural Partners Lined Up Well Ahead In the swirling world of cultural diplomacy, Qatar's got its eyes set way beyond the skyline with their Years of Culture initiative. Announced recently, they've lined up partners through 2030, locking hands with Italy, the Netherlands, Switzerland, Portugal, and Spain in the coming years. Such moves aren't just for show—they’re...

Ractigen's LiCO™ Platform Hits Extrahepatic Milestones

Breaking New Ground in RNA Therapeutics Hey, in the world of biotech, landing a meaningful delivery system is like striking gold, and it seems Ractigen Therapeutics just found a shiny nugget. Their latest study on the LiCO™ platform, living and breathing in the pages of Molecular Therapy - Nucleic Acids, maps out a path to some serious therapeutic territory. These guys...

University of Phoenix Unveils Credit for Prior Learning Advantages

Navigating College Credits with Life Experience If you think school is the only place to pick up education that counts, think again. University of Phoenix is challenging this by recognizing the value of the hustle and grind working adults go through. During the recently wrapped-up National Transfer Student Week, Devin Andrews, their VP of Admissions and Evaluation, shed...

Italian Excellence: NYC Celebrates Innovators and Icons

The Fusion of Italian Artistry and Innovation Imagine blending business savvy with a touch of culture and ethics. That's the spirit of the 9th Business Care International Award, which is gearing up to hit New York City's grand stage come November 18-19. This ain't just about pats on the back; it's a recognition of those who push Italian excellence across oceans and into...